Clinical Trials Logo

Juvenile Idiopathic Arthritis clinical trials

View clinical trials related to Juvenile Idiopathic Arthritis.

Filter by:

NCT ID: NCT03301883 Completed - Clinical trials for Juvenile Idiopathic Arthritis

A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)

Start date: April 26, 2018
Phase: Phase 4
Study type: Interventional

This Phase IV, multicenter, single-arm, open-label study will evaluate the efficacy and safety of tocilizumab in Chinese participants with sJIA with persistent activity and an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) and steroid therapy.

NCT ID: NCT03116763 Completed - Clinical trials for Juvenile Idiopathic Arthritis

The iPeer2Peer Program for Adolescents With Juvenile Idiopathic Arthritis

iPeer2Peer
Start date: March 28, 2017
Phase: N/A
Study type: Interventional

The iPeer2Peer program matches teens with arthritis to an older mentor who has learned to manage their arthritis well and can support them emotionally and socially. This study will compare two groups of teens: those who are in the iPeer2Peer Program and those in the control group (no mentor).

NCT ID: NCT03092427 Active, not recruiting - Clinical trials for Juvenile Idiopathic Arthritis

Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)

PERMAJI
Start date: September 4, 2017
Phase: N/A
Study type: Interventional

This study investigates the efficacy of probiotic VSL#3 as an add on standard care on the activity of the disease in patients with Juvenile Idiopathic Arthritis.

NCT ID: NCT03069638 Completed - Clinical trials for Juvenile Idiopathic Arthritis

Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population

Start date: February 1, 2017
Phase: Phase 4
Study type: Interventional

The main objective of this study is to evaluate the effectivity of intranasal dexmedetomidine sedation during intra-articular injection therapy. Intranasal dexmedetomidine is compared with dinitrous oxide (N2O) which has already been proven safe and effective sedation method during painful procedures in pediatric patients. In earlier studies the median VAS during intra-articular corticosteroid injections with patients receiving nitrous oxide has been 3 (Uziel et al 2008). Study hypothesis is that with intranasal dexmedetomidine sedation the VAS pain levels will be 1 unit lower.

NCT ID: NCT03008681 Completed - Clinical trials for Juvenile Idiopathic Arthritis

OHRQoL Evaluation After Functional Therapy in JIA Patients

Start date: January 2004
Phase: N/A
Study type: Interventional

The aim of the study was to determine the changes in Oral Health-Related Quality of Life (OHRQoL) in patients with juvenile idiopathic arthritis (JIA) and temporomandibular joint (TMJ) disorders who underwent functional therapy for 24 months to assess the age and sex group in which the functional therapy was most effective.

NCT ID: NCT03006991 Recruiting - Clinical trials for Juvenile Idiopathic Arthritis

Study of Methotrexate Given to Juvenile Idiopathic Arthritis Patients Based on Pharmacogenomics and Pharmacometrics

Start date: November 2016
Phase: N/A
Study type: Observational

This study will integrate Pharmacogenomics and Pharmacometrics, to explore an effective concentration of MTXPGn for JIA pediatric patients, and set up a Population Pharmacokinetics model to provide reference for individual administration on JIA pediatric patients.

NCT ID: NCT02991469 Recruiting - Clinical trials for Juvenile Idiopathic Arthritis

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

Start date: August 9, 2018
Phase: Phase 2
Study type: Interventional

Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for adequate treatment of this population. Secondary Objective: To describe the pharmacodynamics (PD) profile, the efficacy, and the long term safety of sarilumab in patients with sJIA.

NCT ID: NCT02977416 Recruiting - Clinical trials for Juvenile Idiopathic Arthritis

Oxidation Rates of the Different Substrates During Exercise in Children and Adolescents With Juvenile Idiopathic Arthritis. Case-control Study and Cases Treated / Cases Not Treated With Anti-TNFα

OSE-JIA
Start date: November 2016
Phase: N/A
Study type: Interventional

During exercise, energy comes mainly from carbohydrates and lipids. The relative contribution of lipids and glucose as energy substrates to exercise depends on the parameters of the exercise (duration, intensity and level of training) and the physiological conditions of the subject. Inflammatory diseases such as juvenile idiopathic arthritis (JIA) are treated, for the most severe forms, by biotherapies. These treatments target certain pro-inflammatory cytokines including TNFα. In adults with rheumatoid arthritis several studies have shown that treatment with anti-TNFα increases insulin sensitivity. There is no data on the oxidation of energy substrates during exercise in children and adolescents with AJI, nor on the impact of anti-TNFα treatments on the oxidation of energetic substrates in children. Investigators hypothesize that, compared to healthy children, children with JIA should exhibit altered oxidation of energy substrates at rest and submaximal physical exercise due to physical deconditioning and inflammation. In addition, those treated with anti-TNFα should have an oxidation profile of energy substrates at exercise different from that of patients not treated with anti-TNFα. Investigators also hypothesize that anti-TNFα treatments modify the contribution of energy chains (aerobic, anaerobic and anaerobic alactic) during the exercise.

NCT ID: NCT02840175 Completed - Clinical trials for Juvenile Idiopathic Arthritis

Treatment Tapering in JIA With Inactive Disease

AJIBIOREM
Start date: May 18, 2017
Phase: Phase 3
Study type: Interventional

As biologic treatments are expensive and associated with some concerns regarding long-term safety, investigator hypothesize that early tapering and then withdrawal of biological agent, in an homogenous group of children with juvenile idiopathic arthritis achieving inactive disease, is safe and not inferior to the maintenance of stable treatment intensity over 24 weeks. In addition, investigator also hypothesize that an earlier tapering of treatment is associated with a better quality-of-life and a general cost saving effect. MRP8/14 will be studied as a potential biomarker for the risk of relapse. A study for biologic agent, anti-biologic agent antibodies and a pharmacogenomic approach will complete the research, as pharmacokinetic study during withdrawal of biologic treatment are rare in children.

NCT ID: NCT02824978 Completed - Clinical trials for Juvenile Idiopathic Arthritis

Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?

ALLIANCE
Start date: October 7, 2016
Phase:
Study type: Observational

to evalute if therapeutic alliance is related to adherence in JIA